Overcoming the Treatment-Risk Paradox for Intensive Blood Pressure Care
MANHASSET, N.Y.–(BUSINESS WIRE)–Patients most likely to benefit from intensive systolic blood pressure treatment (SBP) versus standard treatment to reduce cardiovascular disease (CVD) may also be at risk for adverse events (AE). In an editorial discussing those risks and clinical decisions to pursue intensive care, Joseph Diamond, MD, of The Feinstein Institutes for Medical Research published…
Read More “Overcoming the Treatment-Risk Paradox for Intensive Blood Pressure Care” »